title: Hemophilia in the managed care setting.
abstract: Hemophilia A and B are chronic inherited bleeding disorders that together rank as one of the most expensive chronic diseases in the United States. Factor replacement products, which are the mainstay of treatment, are among the most expensive therapies, with a total annual cost of more than $250,000 per adult patient in the United States. Indirect costs also contribute to the economic burden and include lost productivity, caregivers' unpaid costs, and hemophiliarelated disability. Advances in hemophilia care have resulted in longer survival and a growing patient population, greater complexity in management of the disorder, and rising treatment costs. The establishment of federally recognized Hemophilia Treatment Centers has decreased costs and improved patient outcomes and quality of life by promoting outpatient, preventive, and homebased care. Successful collaboration among providers and managed care programs can improve outcomes and decrease costs for the delivery of hemophilia services.
authors.affiliation: dan_dalton@med.unc.edu.
authors.forename: Dan R
authors.initials: DR
authors.lastname: Dalton
mesh_terms: D000906:Antibodies / Q000097:blood; D001779:Blood Coagulation Factors / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D006467:Hemophilia A / Q000150:complications / Q000191:economics* / Q000628:therapy*; D002836:Hemophilia B / Q000150:complications / Q000191:economics* / Q000628:therapy*; D006801:Humans; D019458:Insurance Coverage; D008329:Managed Care Programs; D010348:Patient Care Team; D010593:Pharmaceutical Services
chemical_list: D000906:Antibodies; D001779:Blood Coagulation Factors